Table 2 Clinicopathological and follow-up data from patients
From: CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma
Pathologic variables | No.of patients |
|---|---|
TNM stage | 129 |
Stage I | 26(20.2%) |
Stage II | 13(10.1%) |
Stage III | 61(47.3%) |
Stage IV | 29(22.5%) |
HCC differentiation | 129 |
WD | 10(7.8%) |
MD | 94(72.9%) |
PD | 25(19.4%) |
Lymph node metastasis | 129 |
Yes | 12(9.3%) |
No | 117(90.7%) |
Vascular invasion | 129 |
Yes | 53(41.1%) |
No | 76(58.9%) |
Extrahepatic metastasis | 129 |
Yes | 37(28.7%) |
No | 92(71.3%) |
Postoperative recurrence | 129 |
Yes | 91(70.5%) |
No | 38(29.5%) |
Cancer related death | 125 |
Death | 81(64.8%) |
Survival | 44(35.2%) |
CAPZA1 expression tatus | 129 |
0 | 13(10.1%) |
1+ | 46(35.7%) |
2+ | 29(22.5%) |
3+ | 26(20.2%) |
4+ | 15(11.6%) |